Zoe Loh1,2, Ortis Estacio3, Andrew Grigg4, Natasha E Holmes5, Geoff Chong4, Eliza A Hawkes4,6. 1. Department of Medical Oncology & Clinical Haematology, Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia. zoeeloh@gmail.com. 2. The University of Melbourne, Parkville, Victoria, Australia. zoeeloh@gmail.com. 3. The University of Melbourne, Parkville, Victoria, Australia. 4. Department of Medical Oncology & Clinical Haematology, Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia. 5. Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. 6. Eastern Health, Box Hill, Victoria, Australia.
Abstract
AIM: To describe the incidence of infective endocarditis (IE) detected on echocardiography in cancer patients with confirmed Staphylococcus aureus bacteraemia (SAB). METHODS: We retrospectively identified 95 cases of SAB in cancer patients from January 2007-March 2016. Echocardiography was ordered at the discretion of the treating team, and positive findings defined according to the Modified Duke Criteria. Complicated bacteraemia was defined by prolonged bacteraemia, presence of intracardiac device/prosthetic valve, or signs of metastatic infection. RESULTS: Major predisposing risk factors for IE (intracardiac device, prosthetic valve, valvular disease, diabetes mellitus, renal dialysis) were present in 27% of cases. Fifty-one of 95 (54%) had a central venous catheter and 17 (18%) patients had complicated bacteraemia. Echocardiography was performed in 75/95 (79%) episodes, with transthoracic echocardiography (TTE) alone in 56, transoesophageal echocardiography (TOE) alone in 4 and both in 15. Echocardiography was diagnostic for IE in 2 patients (1 TTE, 1 TOE), including one result that led to the diagnosis of IE in a clinically unsuspected case. Four further cases of IE were diagnosed on clinical findings, resulting in an overall rate of IE of 6% (6/95). Five of these cases occurred in patients with complicated bacteraemia or ≥ 1 risk factor for IE. No patient was readmitted due to IE. CONCLUSION: IE is infrequent in cancer patients with uncomplicated SAB and no risk factors for IE. Performing echocardiography routinely in all cancer patients with SAB rarely alters diagnosis or affects antibiotic management and therefore should be reserved for patients with specific risk factors.
AIM: To describe the incidence of infective endocarditis (IE) detected on echocardiography in cancerpatients with confirmed Staphylococcus aureus bacteraemia (SAB). METHODS: We retrospectively identified 95 cases of SAB in cancerpatients from January 2007-March 2016. Echocardiography was ordered at the discretion of the treating team, and positive findings defined according to the Modified Duke Criteria. Complicated bacteraemia was defined by prolonged bacteraemia, presence of intracardiac device/prosthetic valve, or signs of metastatic infection. RESULTS: Major predisposing risk factors for IE (intracardiac device, prosthetic valve, valvular disease, diabetes mellitus, renal dialysis) were present in 27% of cases. Fifty-one of 95 (54%) had a central venous catheter and 17 (18%) patients had complicated bacteraemia. Echocardiography was performed in 75/95 (79%) episodes, with transthoracic echocardiography (TTE) alone in 56, transoesophageal echocardiography (TOE) alone in 4 and both in 15. Echocardiography was diagnostic for IE in 2 patients (1 TTE, 1 TOE), including one result that led to the diagnosis of IE in a clinically unsuspected case. Four further cases of IE were diagnosed on clinical findings, resulting in an overall rate of IE of 6% (6/95). Five of these cases occurred in patients with complicated bacteraemia or ≥ 1 risk factor for IE. No patient was readmitted due to IE. CONCLUSION: IE is infrequent in cancerpatients with uncomplicated SAB and no risk factors for IE. Performing echocardiography routinely in all cancerpatients with SAB rarely alters diagnosis or affects antibiotic management and therefore should be reserved for patients with specific risk factors.
Authors: J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey Journal: Clin Infect Dis Date: 2000-04-03 Impact factor: 9.079
Authors: V G Fowler; J Li; G R Corey; J Boley; K A Marr; A K Gopal; L K Kong; G Gottlieb; C L Donovan; D J Sexton; T Ryan Journal: J Am Coll Cardiol Date: 1997-10 Impact factor: 24.094
Authors: Elisabeth Holden; Ahmed Bashir; Ira Das; Hugh Morton; Christopher D Steadman; Peter Nightingale; Richard P Steeds; Miruna D David Journal: J Antimicrob Chemother Date: 2014-03-27 Impact factor: 5.790
Authors: A Incani; C Hair; P Purnell; D P O'Brien; A C Cheng; A Appelbe; E Athan Journal: Eur J Clin Microbiol Infect Dis Date: 2013-02-17 Impact factor: 3.267
Authors: P C Hill; M Birch; S Chambers; D Drinkovic; R B Ellis-Pegler; R Everts; D Murdoch; S Pottumarthy; S A Roberts; C Swager; S L Taylor; M G Thomas; C G Wong; A J Morris Journal: Intern Med J Date: 2001-03 Impact factor: 2.048
Authors: Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Mario Venditti; Marco Falcone; Alessandra Micozzi; Paolo Carfagna; Fabrizio Taglietti; Pietro F Serra; Pietro Martino Journal: Haematologica Date: 2003-08 Impact factor: 9.941